Chronic green tea extract supplementation reduces hemodialysisenhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines

American Journal of Clinical Nutrition

Volumn 86, Issue 5, 2007, Pages 1539-1547

  Hsu, Shih Ping ^a,d   Wu, Ming Shiou ^a   Yang, Chih Ching ^b,e   Huang, Kuo Chin ^a   Liou, Shaw Yih ^c   Hsu, Su Ming ^a   Chien, Chiang Ting ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c Formosan Blood Purification Foundation   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Antiinflammation; Catechins; Hemodialysis; Oxidative stress; Proinflammation

Indexed keywords

ASCORBIC ACID; C REACTIVE PROTEIN; CATECHIN; CYTOKINE; GREEN TEA EXTRACT; HYDROGEN PEROXIDE; HYPOCHLOROUS ACID; PHOSPHATIDYLCHOLINE; PLACEBO;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE;

EID: 36248977720     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/86.5.1539     Document Type: Article

References (46)

1. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-86.
2. Sela S, Shurtz-Swirski R, Shapiro G, et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int 2001;78(suppl):S159-63.
3. Himmelfarb J, Lazarus JM, Hakim RM. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during hemodialysis. Am J Kidney Dis 1991;7:271-6.
4. Huang KC, Yang CC, Lee KT, Chien CT. Reduced hemodialysisinduced oxidative stress in end-stage renal disease patients by electrolyzed reduced water. Kidney Int 2003;64:704-14.
5. Chien CT, Chang WT, Chen HW, et al. Ascorbate supplement reduces oxidative stress in dyslipidemic patients undergoing apheresis. Arterioscler Thromb Vasc Biol 2004;24:1111-7.
6. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987;84:2995-8.
7. Fogelman AM, Shechter I, Seager J, et al. Malondialdehyde alteration of low density lipoprotein leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A 1980;77:2214-8.
8. Galle J, Bassenge R, Busse R. Oxidized low-density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res 1990;66:1287-93.
9. Schoonbroodt S, Legrand-Poels S, Best-Belpomme M, Piette J. Activation of the NF-kappaB transcription factor in a T-lymphocytic cell line by hypochlorous acid. Biochem J 1997;321:777-85.
10. Galli F, Benedetti S, Floridi A, et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int 2005;67:750-9.
11. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236-44.
12. Futh R, Herder C, Forster S, et al. Evaluation of diagnostic relevance of mRNA concentrations in peripheral blood: predictive value for mortality in hemodialysis patients. Cytokine 2004;27:166-72.
13. Jialal I, Fuller CJ, Huet BA. The effect of α-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995;15:190-8.
14. Ohigashi H, Murakami A. Cancer prevention with food factors: alone and in combination. Biofactors 2004;22:49-55.
15. D'Alessandro T, Prasain J, Benton MR, et al. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr 2003;133(suppl):3773S-7S.
16. Hertog MG, Feskens EJ, Hollman PC, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007-11.
17. Chen WC, Hayakawa S, Shimizu K, et al. Catechins prevents substance P-induced hyperactive bladder in rats via the downregulation of ICAM and ROS. Neurosci Lett 2004;367:213-7.
18. Yu HJ, Lin BR, Lee HS, et al. Sympathetic vesicovascular reflex induced by acute urinary retention evokes proinflammatory and proapoptotic injury in rat livers. Am J Physiol Renal Physiol 2005;288:F1005-14.
19. Nakagawa K, Ninomiya M, Okubo T, et al. Tea catechin supplementation increases antioxidant capacity and prevents phospholipid hydroperoxidation in plasma of humans. J Agric Food Chem 1999;47:3967-73.
20. Torgerson DJ, Campbell MK. Use of unequal randomisation to aid the economic efficiency of clinical trials. BMJ 2000;321:759.
21. Sutherland WH, Walker RJ, de Jong SA, et al. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 1999;19:1340-7.
22. Sutherland WH, de Jong SA, Walker RJ. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 2004;19:75-82.
23. Yang CC, Hsu SP, Wu MS, Chien CT. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int 2006;69:706-14.
24. Watson AD, Leitinger N, Navab M, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low-density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997;272:13597-607.
25. Rabovsky A, Cuomo J, Eich N. Measurement of plasma antioxidant reserve after supplementation with various antioxidants in healthy subjects. Clin Chim Acta 2006;371:55-60.
26. Busch M, Franke S, Muller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004;66:338-47.
27. Piotrowski JJ, Shah S, Alexander JJ. Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Life Sci 1996;58:735-40.
28. Lee CM, Chien CT, Chang PY, et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen freeradical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005;183:251-8.
29. Lehr HA, Frei B, Olofsson AM, et al. Protection from oxidized LDL-induced leukocyte adhesion to microvascular and macrovascular endothelium in vivo by vitamin C but not by vitamin E. Circulation 1995;91:1525-32.
30. Siow RC, Richards JP, Pedley KC, et al. Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high concentrations of lipid hydroperoxides. Arterioscler Thromb Vasc Biol 1999;19:2387-94.
31. Meyers DG, Maloley PA, Weeks D. Safety of antioxidant vitamins. Arch Intern Med 1996;156:925-35.
32. Canavese C, Petrarulo M, Massarenti P, et al. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients. Am J Kidney Dis 2005;45:540-9.
33. Ludwig A, Lorenz M, Grimbo N, et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004;316:659-65.
34. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003;133(suppl):3275S-84S.
35. Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002;39:653-63.
36. Memoli B, Grandaliano G, Soccio M, et al. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD. J Am Soc Nephrol 2005;16:1099-107.
37. Ferrucci L, Cherubini A, Bandinelli S, et al. Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 2006;91:439-46.
38. Hurst SM, Wilkinson TS, McLoughlin RM, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14:705-14.
39. Kusner DJ, Luebbers EL, Nowinski RJ, et al. Cytokine- and LPSinduced synthesis of interleukin-8 from human mesangial cells. Kidney Int 1991;39:1240-8.
40. Ben-Baruch A, Bengali K, Tani K, et al. IL-8 and NAP-2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL-8 receptor type A or type B. Cytokine 1997;9:37-45.
41. Ohlsson K, Bjork P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
42. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991;12:404-10.
43. Malyak M, Smith MF Jr, Abel AA, Arend WP. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 beta. J Clin Immunol 1994;14:20-30.
44. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-62.
45. Van Zee KJ, Kohno T, Fischer E, et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992;89:4845-9.
46. Pereira BJ. Cytokine production in patients on dialysis. Blood Purif 1995;3:135-46.